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FANCC REGULATES THE SPINDLE ASSEMBLY CHECKPOINT TO PREVENT 
TUMORIGENESIS IN VIVO 
 
The Fanconi anemia (FA) pathway consists of 21 genes that maintain genomic stability 
and prevent cancer. Biallelic mutations within this network cause Fanconi anemia, an 
inherited bone marrow failure and cancer predisposition syndrome. Heterozygous inborn 
mutations in FA genes increase risk of breast/ovarian cancers, and somatic mutations 
occur in malignancies in non-Fanconi patients. Understanding the tumor suppressive 
functions of FA signaling is important for the study of Fanconi anemia, inherited cancers, 
and sporadic cancers. 
 
 
The FA network functions as a genome guardian throughout the cell cycle. In addition to 
the well-established roles of FA proteins in interphase DNA replication/repair, the FA 
pathway controls mitosis by regulating the spindle assembly checkpoint (SAC) to ensure 
proper chromosome segregation. The SAC consists of several tumor suppressors, 
including Mad2, and SAC impairment predisposes to aneuploidy and cancer. However, 
the in vivo contribution of SAC dysfunction to malignant transformation of FA-deficient 
cells remains unknown. Furthermore, the mechanisms by which FA proteins regulate the 
SAC are unclear. 
 
 
To test whether SAC dysfunction drives genomic instability and tumorigenesis in FA, we 
generated a novel FA-SAC model by intercrossing Fancc-/- and Mad2+/- mice. The 
vi  
intercrossed mice displayed heightened aneuploidy secondary to exacerbated SAC 
dysfunction. Importantly, these mice were prone to developing hematologic 
malignancies, particularly leukemia, faithfully recapitulating the clinical phenotype of 
Fanconi anemia. 
 
 
Upon establishing SAC dysfunction as a driver of tumorigenesis in FA, we next explored 
the mechanism by which FANCC regulates the SAC. We demonstrated that the mitotic 
kinase CDK1 phosphorylates FANCC to regulate subcellular localization and SAC 
function of FANCC during mitosis. 
 
 
Our study highlights the essential role of compromised chromosome segregation in the 
development of leukemia due to impaired FA signaling. This work furthers our 
knowledge of FANCC signaling at the SAC, and has implications for future use of 
mitotic-centered therapies for FA-associated tumors. 
 
 
D. Wade Clapp, M.D., Chair 
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                CHAPTER ONE 
 
                INTRODUCTION 
 
Fanconi anemia: clinical features 
 
Fanconi anemia (FA) is a complex genetic disorder of genomic instability, resulting in 
bone marrow failure, congenital abnormalities, and cancer predisposition in patients. FA 
has a reported incidence of 10 cases per 1 million people and a carrier frequency of 1:181 
in the US (1). The classical clinical hallmark of Fanconi anemia is bone marrow failure 
(BMF), with a cumulative incidence of 90% by age 40 (2). Impaired hematopoiesis in the 
bone marrow can manifest in patients as pallor, anemia, frequent bruising or infections 
due to low blood counts. Other frequent hematologic abnormalities include 
myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) with or without 
pre-existing anemia (2). A variety of congenital abnormalities are also often seen in FA 
patients, including microcephaly, micropthalmia, short stature, and structural 
malformations of the thumbs, radii and ears (2, 3). Additionally, up to 1/3 of FA patients 
have physical findings consistent with VACTERL-H association (vertebral anomalies, 
anal atresia, congenital heart disease, trachea-esophageal fistula, esophageal atresia, 
renal/limb abnormalities, and hydrocephalous) (3). Notably, FA is associated with a 
heightened risk of cancer. The most common cancers seen in FA patients are AML and 
squamous cell carcinomas (head and neck and gynecological) (4). 
 
 
The clinical standard for diagnosis of FA is a positive chromosome breakage test (5). 
This test is based on our knowledge that exposure to DNA crosslinking agents such as 
mitomycin c (MMC) or diepoxybutane (DEB) will cause chromosome fragmentation in 
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FA patient cells while having little effect on non-FA cells. Median age at diagnosis is 6.5 
years (6), though FA patients may remain undiagnosed until adulthood upon onset of 
malignancy (7, 8). The vast clinical heterogeneity of this disease (Fig. 1) makes it likely 
that FA is under-diagnosed. 
 
 
Management for FA patients has drastically improved with our increasing knowledge of 
disease pathogenesis, though median overall survival is still only 33 years (4). 
Progressive BMF may require an allogeneic hematopoietic stem cell transplant (HSCT). 
Because of sensitivity to chemotherapeutic agents and graft-versus-host disease, FA 
patients experience high toxicity with standard conditioning regimens prior to transplant 
(6), and thus transplants must be tailored. Gene therapy may also be a future option with 
clinical trials underway (9). 
 
 
Fanconi anemia: genetics 
 
The underlying genetics driving a diagnosis of FA are as complex as its clinical 
presentation. Swiss pediatrician Guido Fanconi published a case report of a family with 
three children with congenital abnormalities and anemia who all died young. Dr. Fanconi 
was the first to identify this strange constellation of symptoms as one disease, which 
became known as Fanconi anemia (10). It was not until the early 1990s that the FANCC 
gene was first discovered and cloned (11, 12), and cloning of the FA core complex genes 
FANCA, FANCG, FANCE, and FANCF soon followed (13-17). Importantly, both BRCA1 
(also known as FANCS) and BRCA2 (also known as FANCD1) of the breast/ovarian 
cancer susceptibility pathway have been characterized as FA genes (18-20). With now 21 
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known FA genes, including the identification of UBE2T/FANCT (21-23), REV7/FANCV 
(24), and XRCC2/FANCU (25) all discovered in the last few years, work into defining the 
FA pathway and its functions has exploded. 
 
 
Biallelic inactivation of any of the FA genes causes the disease Fanconi anemia; 
however, genetic disruption of the FA pathway is also seen in broader patient populations 
as well. Germline heterozygous FA mutation carriers have an increased risk of 
developing cancer. Cancer risk by age 70 for BRCA1/FANCS mutation carriers is 
estimated at 65% for breast cancer and 39% for ovarian cancer (26). Similarly, PALB2 
(FANCN) is both a breast cancer and pancreatic cancer susceptibility gene (27, 28). In 
addition to inherited cancer risks in germline FA mutations, somatic mutations and 
epigenetic silencing of FA genes are common in sporadic cancers, such as pancreatic 
cancer and squamous cell carcinomas (29-31). Understanding the tumor suppressive 
functions of the FA pathway (Fig. 2) is then important for furthering our knowledge of 
Fanconi anemia, inherited cancers, and cancers with sporadic mutations in FA genes. 
 
 
Fanconi anemia: cellular features 
 
Underlying the clinical and genetic heterogeneity of this disease is a unifying problem of 
genomic instability (Fig. 1). The FA pathway members have been dubbed the “guardians 
of the genome” for their diverse role in protecting the cell’s genomic integrity from 
genotoxic insults. In its most studied role, the FA pathway functions in a DNA repair 
network during interphase to recognize and repair interstrand crosslinks (ICLs) through 
homologous recombination. Briefly, FANCM recognizes ICL lesions in DNA and serves 
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as a homing platform for the binding of the FA core complex (FANCA, FANCB, 
FANCC, FANCE, FANCG, FANCL, FANCM, FANCT, FAAP100, MHF1, MHF2, 
FAAP20 and FAAP24). The core complex serves as an ubiquitin ligase to mono- 
ubiquitinate FANCD2 and FANCI, thereby recruiting endonucleases and facilitating 
homologous recombination (Rev. in (32, 33)). 
 
 
In addition to their role in repairing double-strand break (DSB) DNA damage when it 
occurs, there is mounting evidence that the FA pathway prevents cellular harm from 
replication stress and reactive oxygen species. The FA pathway stabilizes stalled 
replication forks during interphase, preventing fork collapse and DSB break formation, 
and further protecting genomic integrity (32). FA genes also insulate the promoters of 
antioxidant defense genes from oxidative damage (34), and exposure to oxidative stress 
spurs apoptosis of FA-deficient hematopoietic cells (35). In particular, FA-deficient cells 
display hypersensitivity to aldehyde exposure, an endogenous source of ICLs (36). 
Presence of a variant non-functioning ALDH2 allele in Japanese FA patients was found 
to be associated with heightened BMF progression (37). FANCC is also required for 
autophagic clearance of viruses, and multiple FA proteins have a role in mitophagy, to 
decrease mitochondrial reactive oxygen species (ROS) (38). 
 
 
In addition to protecting against replication/repair stress and oxidative stress, FA 
signaling also protects the cell from inflammatory-mediated stress. FANCC in particular 
protects HSCs from IFN- γ and TNF- α mediated cytotoxicity (39), and Fancc-/- murine 
hematopoietic progenitor cells demonstrate hypersensitivity and increased apoptosis upon 
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exposure to inflammatory cytokines (40, 41). This cellular hypersensitivity, coupled with 
the fact that FA patient hematopoietic cells express high levels of IFN- γ and TNF- α (42), 
creates a toxic “cytokine storm” cellular environment. 
 
 
Evidence is accumulating to support the notion of the FA pathway members as guardians 
of the genome, not only for their protective roles in interphase, but also for proper 
execution of mitosis. During mitosis, certain FA proteins localize to various parts of the 
mitotic apparatus, including the centrosome, spindle, and mitotic kinetochore (43, 44). In 
early mitosis, centrosomes serve as the spindle poles to anchor the developing spindle 
and microtubules undergo a “search and capture” process to capture the chromosomes 
and attach them to the spindle in the proper orientation. The FA pathway has been 
recently implicated in maintenance of centrosomal integrity upon the observation of 
centrosome amplification upon loss of various FA proteins (45-48). Phosphorylation of 
FANCA by the mitotic kinase NEK2 protects centrosomal integrity (46), and 
BRCA2/FANCD1 works in concert with centrosomal proteins NPM and ROCK2 to 
regulate centrosome number (47). In the context of DNA damage, FANCJ recruits 
BRCA1/FANCS and PLK1 to the centrosome to prevent centrosome amplification (48). 
Increased centrosome number can result in abnormal kinetochore-microtubule 
attachments and chromosome missegregation (49). As kinetochore-microtubule 
attachments form and chromosomes align, the spindle assembly checkpoint (SAC) is 
activated to delay anaphase until all chromosomes have been properly attached to the 
mitotic spindle. A functional SAC is necessary to ensure proper chromosome 
segregation, and the majority of the FA proteins have been shown to regulate SAC 
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function (43). Impairment of the SAC results in aneuploidy due to chromosome 
missegregation and promotes cancer (50), and accordingly, FA pathway-deficient cells 
demonstrate defective SAC function and aneuploidy (43, 44) (Fig. 3). Upon onset of 
anaphase, some FA proteins act to resolve ultrafine anaphase bridges (UFBs), which are 
abnormal structures thought to have formed from unresolved replication errors (51-53). 
Additionally, an intact FA pathway is necessary for proper cytokinesis. The presence of 
chromatin at the site of cytokinetic cleavage (due to chromosome missegregation) can 
block cytokinesis (54). FA pathway-deficient cells fail to complete cytokinesis (53, 55- 
57), and certain FA proteins, such as FANCC and BRCA2, localize to the cytokinetic 
midbody (43, 56). Thus the FA pathway functions at many phases throughout mitosis to 
preserve genomic integrity and ensure mitotic fidelity. 
 
 
Aneuploidy is known to be both a cause and consequence of cancer (reviewed in (50)). 
As early as 1914, Theodor Boveri proposed that aneuploid cells are the founding cells of 
tumors, describing his hypothesis that “the primordial tumorigenic cell…is a cell that 
harbours a specific faulty assembly of chromosomes as a consequence of an abnormal 
event” (58). Chromosomal instability (CIN) refers to an ongoing change in the 
chromosomal makeup over rounds of division. As chromosomal makeup changes over 
time, cells can acquire alterations in their transcriptome and proteome that allow for a 
proliferative advantage, such as the loss of a tumor suppressor, and promote 
tumorigenesis. While aneuploidy is observed to be extremely common among cancer 
cells, it also can cause proliferative disadvantage and p53 activation (reviewed in 
7  
 
 
 
 
 
 
7 
(59). This “aneuploidy paradox” is parallel to the disease scenario of Fanconi anemia, a 
disease of BMF and heightened cancer predisposition. 
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Figure 1. The FA clinical phenotype (left) and the FA cellular phenotype (right) are 
highly complex. 
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Figure 2. Bilallelic inactivation, germline heterozygosity, or somatic mutations in FA 
can all contribute to cancer predisposition. 
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Figure 3. The SAC acts as a “halt signal” delaying anaphase until all chromosomes 
are properly attached to the mitotic spindle. In FA-deficient cells, the SAC is 
dysfunctional, promoting genomic instability. 
11  
 
 
 
10 
Mouse models of FA 
 
Our knowledge of the FA pathway family members as guardians of the genome has 
informed our understanding of FA disease pathogenesis. Much of our knowledge of FA 
disease pathogenesis comes from the use of in vivo murine models. Single gene knock 
out models exist for most of the FA pathway genes and have been well characterized 
(reviewed in (60)). Brca1/Fancs knock out mice, generated by a hematopoietic-driven 
Cre, demonstrate genomic instability, bone marrow failure and develop hematologic 
malignancies (61). Single gene knockouts of FA core complex genes, however, while 
effective in capturing the cellular and molecular FA phenotypes, overall do not robustly 
model the clinical phenotype seen in patients. Fanca-/-, Fancc-/- and Fancg-/- single 
gene knock-out mice show decreased fertility, yet do not develop BMF or heme 
malignancies within the first year of life (62-64). A modest fraction of aged Fancc-/- 
mice do spontaneously develop leukemias/lymphomas (65). 
 
 
Instead, intercrosses of mice lacking different FA genes with mice lacking other genes as 
well as pharmacologic challenge of single FA gene KO models have provided great 
mechanistic insight and overall more effectively modeled FA cancer and BMF 
predisposition. Fancc-/-,Fancg-/- mice develop spontaneous BMF and AML and have 
genomic instability (66), suggesting that certain FA genes may have cooperative tumor 
suppressive roles. However Fancc-/- Fanca-/- mice are phenotypically identical to single 
knockouts (67), providing evidence that certain individual FA genes are functionally 
epistatic with each other. 
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Mouse models have demonstrated that DNA damage can drive disease in a FA-deficient 
background. MMC treatment sparks BMF in Fancc-/- mice (68). Ionizing radiation 
induces p53 expression in Fancc-/- mice, and loss of both Fancc and p53 accelerate 
tumorigenesis in a murine model (69). Likewise, p53 heterozygosity accelerates 
tumorigenesis in Fancd2-/- mice (70). 
 
 
Multiple recently developed mouse models have demonstrated the protective role of FA 
signaling in the face of oxidative stress. Mice deficient for both Fancc and Sod1, a 
superoxide-detoxifying enzyme, exhibit impaired hematopoiesis in the context of 
increased reactive oxygen species (ROS) (71). Aldh2-/-Fancd2-/- mice spontaneously 
develop leukemias and acetyaldehdye exposure causes BMF secondary to DNA damage 
in Aldh2-/- Fancd2-/- mice (72). Aged Aldh2-/-Fancd2-/- mice spontaneously develop 
BMF, and demonstrate decreased numbers of hematopoietic stem cells (HSCs) and DNA 
damage in the HSCs (73). Interestingly, treatment with the diabetes drug metformin, 
which can mitigate aldehyde toxicity, increased the frequency of HSCs in Fancd2-/- mice 
and delayed tumorigenesis in Fancd2-/-, p53+/- mice (74). Taken together, these studies 
demonstrate that oxidative stress causes BMF and leukemogenesis in FA in vivo. 
 
 
Mouse models have also furthered our understanding of the in vivo signaling that occurs 
upon loss of FA and drives BMF. In response to replicative stress and DNA damage, p53 
is hyperactivated in FA cells and triggers G0/G1 cell cycle arrest, leading to exhaustion 
of the HSC pool and BMF (75). Hyperactive TGFbeta signaling is also contributory to 
HSC impairment in FA. Inhibiting TGFbeta signaling rescues the functional defects of 
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HSCs from Fancd2-/- mice and rescues physiological stress-induced BMF (76). Another 
mechanism driving BMF in FA murine models is inhibitory cytokine hypersensitivity and 
apoptosis of Fancc-/- hematopoietic progenitors (40). 
 
 
While models exist to understand the contribution of various interphase roles of FA 
signaling as in vivo guardians of the genome, little work has been done to investigate 
whether abnormal mitosis upon loss of FA signaling could contribute to disease in vivo. 
Work by Choi et al (2012) has uncovered a role for BRCA2/FANCD1 in facilitating 
acetylation of the kinetochore protein BubR1 to regulate the SAC, and demonstrated that 
a mouse model lacking BRAC2-BUBR1 binding ability spontaneously develops various 
tumors and genomic instability (77, 78). This is a promising lead, however, it remains 
unknown whether the FA core complex members, such as FANCC, modulate the SAC to 
prevent tumorigenesis. Also there is a need for an FA-SAC model that more closely 
resembles the hematopoietic-specific diseases of FA patients. 
 
 
There is still a great need for targeted therapies for FA patients and patients with FA- 
deficient cancers. Recent evidence demonstrates that FA signaling regulates the SAC, 
and SAC dysfunction is a known cause of malignancy. However, the in vivo significance 
of SAC dysfunction in FA signaling remains unclear. Thus we set out to establish a new 
FA-SAC mouse model to 1) test whether SAC dysfunction can drive genomic instability 
and tumorigenesis in FA in vivo, and 2) provide a rationale to explore new mitotic- 
centered therapies for FA-associated malignancies. We genetically weakened the SAC in 
the FA-deficient background by generating Fancc-/-;Mad2+/- intercrossed mice. Mad2 is 
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a tumor suppressor well known for its role in regulating the SAC (79) without directly 
affecting interphase DNA damage repair. Mad2 heterozygosity in the Fancc-/- 
background allows us to further impair only one pathway (SAC) out of the multiple 
tumor suppressor networks (such as SAC and DDR) affected by loss of FA signaling, in 
order to determine whether SAC dysfunction drives tumorigenesis in the context of FA. 
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MATERIALS AND METHODS 
 
 
Mice 
 
Mad2+/- and Fancc-/- mice (C57Bl/6J background) were a gift of D. Wade Clapp 
(Indiana University). Mice were genotyped via PCR as previously described (66). 
B6.SJL-PtprcaPepcb/BoyJ mice were purchased from the Indiana University In Vivo 
Therapeutics Core. All studies were performed in accordance with the policies of the 
institutional animal care and use committee of Indiana University. 
 
 
Peripheral blood assays 
 
Peripheral blood was drawn from the lateral tail vein and collected into EDTA-coated 
collection tubes. Complete blood counts were obtained using a Hemavet 950FS (Drew 
Scientific). Blood was smeared onto slides, stained with Geisma, and imaged using a 
Zeiss Axiolab microscope. 
 
 
For chimerism analysis, peripheral blood was collected monthly post-transplant as 
described above. Cells were stained with anti-CD45.2-FITC (BD Biosciences) and anti- 
CD45.1-PE (BD Biosciences) as previously described (66), and analyzed on a 
FacsCalibur machine (Becton-Dickinson).  For lineage classification of WBCs, the 
following antibodies were used: anti-CD3e (BD Bioscience), anti-B220 (clone RA3-6B2, 
BD Pharmingen), anti-cd11b (clone M1/70, eBioscience), anti-Ly-6G/Ly-6C (clone RB6- 
8C5, Biolegend). At least 10,000 events per sample were acquired. Data was analyzed 
using FlowJo Software. 
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Bone marrow transplantation 
 
For competitive repopulation studies, 1.5x106 donor test LDMNCs (C57Bl/6J 
background) and 1.5x106 donor competitor LDMNCs (BoyJ background) were 
transplanted into each recipient mouse via tail vein injection. Recipients were 8 week-old 
female B6.SJL-PtprcaPepcb/BoyJ mice that underwent whole-body split-dose 1100 rads 
irradiation (700 rads/400 rads, 4 hours apart). For transplant of leukemic marrows, 0.5-1 
million donor cells were transplanted into lethally irradiated recipient female B6.SJL- 
PtprcaPepcb/BoyJ mice with CD45.1+ wt competitor cells at a ratio of 1:1 or 1.4:1 
donor:competitor. 
 
 
Bone marrow harvesting 
 
Bone marrow cells were flushed from tibias and femurs of mice using a 23-gauge needle 
and syringe (Becton Dickinson). LDMNCs were isolated by density gradient using 
Histopaque-1119 (Sigma), centrifuging for 30 minutes at 1800rpm with no brake.  After 
centrifugation, LDMNCs were removed from the interface layer and either utilized for 
transplantation or culturing.  Murine cytospins were made by resuspending LDMNCs in 
PBS and centrifuging onto slides at 450rpm for 5 minutes on a Shandon Cytospin 3 
Cytocentrifuge (Thermo Scientific). 
 
 
Histology 
 
Tissues collected from mice post-mortem were fixed in 10% formalin and subsequently 
embedded in paraffin, sectioned (5uM sections), and stained with hematoxylin and eosin 
(H & E). The following antibodies were used for immunohistochemistry staining: anti- 
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ckit (C19, Santa Cruz, 1:50), anti-cd11b (Novus Biologicals, 1:50), CD3 (Dako IR503), 
B220 (Clone RA3-6B2, BD-550286). Peripheral blood smears and bone marrow 
cytospins were stained with Geisma using the automated Siemens Hematek 3000 (Fisher) 
system. 
 
 
Diagnoses of leukemia and lymphoma were made using criteria established in the 
Bethesda proposals for classification of nonlymphoid neoplasms in mice (80), and the 
Bethesda proposals for classification of lymphoid neoplasms in mice (81). Diagnoses 
were confirmed by a hematopathologist at IU School of Medicine. 
 
 
Hematopoietic progenitor assay 
 
20,000 LDMNCS were plated in triplicate onto 35x10mm culture dishes with 2mm grids 
(Thermo Scientific) and grown in methycellulose (H4100 STEMCELL) media in IMDM 
containing the following: 100ng/ml m-SCF, 10ng/ml mGM-CSF, 5ng/ml mIL-3, 4 
units/ml EPO, 20mM glutamine, 0.00005% βME, 30% FBS, 1% P/S and MMC at 
indicated concentrations. The cells were incubated at 37oC and 5% CO2 for 7 days and 
then scored. A colony was defined as a cluster of ≥50 cells. 
 
 
Metaphase spreads 
 
Bone marrow cells flushed from tibias were cultured in IMDM supplemented with 20% 
FBS, murine stem cell factor (100ng/ml), and IL-6 (200ng/ml) for 2 days.  Cells were 
then exposed to 0.2ug/ml colcemid (Life Tech) for 4 hours and pelleted at 800 rpm for 5 
minutes. Cells were resuspended dropwise in pre-warmed (37oC) 75mM KCl while 
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vortexing gently, and incubated at 37oC for 15 minutes. After pelleting, cells were 
resuspended in a 3:1 methanol: glacial acetic acid fixative solution. Cells were pelleted 
and resuspended in fixative solution two additional times before being dropped onto 
slides and dried overnight. Spreads were then stained with Vectashield mounting medium 
with Dapi (Vector Laboratories). For the chromosome breakage test, cells were cultured 
for 48 hours in 50nM MMC before addition of colcemid. For spectral karyotyping 
(SKY), samples were prepared as above and imaged and analyzed by the MD Anderson 
Cancer Center Molecular Cytogenetics Facility. 
 
 
SAC escape imaging studies 
 
Ckit+ cells were isolated from LDMNC population by MACs sorting (mouse CD117 
magnetic beads, Miltenyi Biotec), and cultured for 24 hours in 10% FBS, 1% P/S, 
100ng/ml TPO, 100ng/ml SCF, and 100ng/ml Flt3 in RPMI media. The cells were then 
pulsed with 10uM EDU for 2 hours, followed by treatment with 100ng/ml nocodazole for 
12 hours. Cell fixation and EDU staining was performed using the Click-it Edu imaging 
kit (Thermo scientific), followed by staining with pHH3 antibody conjugated to Alexa 
647 (Cell signaling, 1:50). Cells were spun onto coverslips via cytospin at 450rpm for 
5min, and then mounted onto coverslips with ProLong Diamond Antifade mountant with 
Dapi (Thermo). EDU+ cells were counted on the deconvolution microscope at 100x. 
BMDMs were obtained by culturing the LDMNCs in IMDM supplemented with 20% 
FBS, 10ng/ml M-CSF, and 1%P/S for 7 days. 
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Microscopy 
 
Images of murine blood smears, cytospins, and histological sections were obtained using 
a Zeiss Axiolab microscope containing a color camera. 
 
 
Images of metaphase spreads were acquired on a Deltavision personalDx deconvolution 
microscope (Applied Precision) furnished with 20x, 60x, 100x and a CCD camera. Image 
stacks (distance between z-sections: 0.2μm) were deconvolved using Softworx software 
suite (10 iterations; ratio: conservative) and analyzed using Imaris software suite 
(Bitplane). For observation of duration of mitosis, a Biostation IMQ live imaging 
microscope (Nikon) with a z220 workstation (Hewlett Packard) and an attached 37oC 
incubator was used. Phase contrast image stacks (distance between z sections: 2 μm) were 
captured in two-minute intervals for up to 24 hours. Videos were analyzed using NIS- 
Elements Viewer software. 
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RESULTS 
 
 
Genetic disruption of Fancc and Mad2 cooperate to promote hematologic 
malignancies 
Fancc-/- mice are viable with a mild impairment in the SAC (44) and develop cancer late 
in life (60, 63, 68). Mad2-/- mice are embryonic lethal due to severe aneuploidy (82), 
while Mad2+/- mice display only a mild predisposition for tumorigenesis late in life and 
modestly impaired SAC function (79). If error-prone chromosome segregation 
contributes to leukemogenesis in FA, Fancc-/-; Mad2+/- mice should be more prone to 
cancer than age-matched wt, Fancc-/-, and Mad2+/- animals (Fig. 4). 
Due to known impaired fertility of the Fancc-/- genotype, we crossed Fancc+/- mice  
with Fancc+/-; Mad2+/- mice to obtain Fancc-/-; Mad2+/- mice. Importantly, a 24- 
month observation study of cohorts of Fancc-/-; Mad2+/- mice alongside wt; Mad2+/-; 
and Fancc-/- cohorts revealed shortened life span of Fancc-/-; Mad2+/- animals (Fig. 5B, 
p < 0.0001). These mice were dying prematurely due to hematologic malignancies (Table 
1), mainly myeloid leukemias (Fig. 6). Moribund Fancc-/-; Mad2+/- mice were 
diagnosed with myeloid leukemia according to Bethesda criteria ((80), Fig. 7). These 
mice had splenomegaly (Fig. 6A), and a predominance of blasts (Fig. 6B) and myeloid 
cells expressing lineage surface markers Gr1 and Mac1 in the peripheral blood (Fig. 6C- 
D). We also observed myeloid cell infiltrates into the liver and spleen, and increased 
ckit+ staining by bone marrow immunohistochemistry, suggestive of an expansion of 
precursor cells in the marrow (Fig. 6E).  Importantly, transplant of leukemic Fancc-/-; 
Mad2+/- bone marrow cells to healthy irradiated recipients was lethal to recipient mice. 
Recipients displayed a myeloid skewing in the peripheral blood, leukemic liver 
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infiltrates, and myeloid takeover of the bone marrow similar to disease presentation in the 
donor mouse (Fig. 8, Table 2). Additionally, a subset of Fancc-/-; Mad2+/- mice, 
particularly >1 year of age, died of lymphoid leukemia/lymphoma. These mice had large 
abdominal masses containing lymphoid cells, CD3+ or B220+ hematopoietic infiltrates in 
the liver, and an unusual population of CD3low+B220low+ cells in the peripheral blood 
(Fig. 9). 
 
 
Sick Fancc-/-; Mad2+/- mice also displayed additional hematologic abnormalities, 
including cytopenias, decreased bone marrow cellularity, and decreased colony forming 
potential in methylcellulose progenitor assays (Fig. 10). Interestingly healthy 2-3 month 
old Fancc-/-; Mad2+/- mice do not display these abnormalities, and have blood counts, 
cellularity and progenitor function comparable to age-matched wt or single mutant 
(Fancc-/- or Mad2+/-) mice until acute disease (Fig. 10). 
 
 
To study in further detail specifically the malignant potential of Fancc-/-; Mad2+/- 
hematopoietic cells, we performed competitive repopulation transplant experiments. 
Bone marrow test cells (CD45.2+) from Fancc-/-; Mad2+/- mice or controls (wt; Fancc- 
/-; or Mad2+/-) were transplanted into lethally-irradiated wt recipients along with wt 
competitor (CD45.1+) cells (Fig. 11A). After transplantation, peripheral blood CD45.2 vs 
CD45.1 chimerism was compared monthly to determine the ability of the donor test cells 
to outcompete competitor cells and stably reconstitute hematopoiesis in the recipient 
marrows. 
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Post transplant, individual recipient mice that received the genomically unstable Fancc-/- 
 
; Mad2+/- hematopoietic stem cells displayed a wide variation (Bartlett’s test, p=0.0178) 
in chimerism, while recipients of control test cells (wt; Mad2+/- or Fancc-/-) showed 
similar levels of chimerism among individual recipients (Fig. 11B). Additionally, by 1 
year post-transplant, the transplanted CD45.2+ Fancc-/-; Mad2+/- cells were producing 
WBCs that were predominantly myeloid, as assessed by flow cytometry of peripheral 
blood for lineage markers CD11b, Gr-1, CD3, and B220 (Fig. 11C-D), suggestive of 
clonal evolution in these animals. Indeed, MDS was found in 64.3% of Fancc-/-; 
Mad2+/- recipients at time of necropsy, as compared to 0% of recipients of wt, Mad2+/- 
or Fancc-/- marrow (Fig. 11E). CD45.2+ Fancc-/-; Mad2+/- donor test cells showed 
impaired colony-forming ability in methycellulose assays (Fig. 11F), indicating impaired 
HSC function. The findings of varied recipient chimerism, MDS post-transplant and 
functional impairment in Fancc-/-; Mad2+/- HSCs supports the notion that deficiency of 
these two SAC regulators cooperates to disrupt proper hematopoiesis. 
 
 
Thus we have established a novel FA mouse model that reflects the FA clinical 
manifestations of cancer predisposition (particularly leukemias) and impaired 
hematopoiesis due to impaired SAC. 
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Figure 4. Schematic of Fancc-/-; Mad2+/- intercross detailing known phenotypes of 
single gene mutant mice. 
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Figure 5. Fancc-/-; Mad2+/- mice have shortened life span and succumb to 
hematologic malignancies. The p value at 24 months was calculated by log rank Mantel- 
Cox test (n ≥ 17 mice/genotype). Symbols represent individual diagnoses at time of 
death. 
  
 
 
 
 
 
Summary of Fancc-/-; Mad2+/- individual moribund mice with hematologic malignancies 
Mouse ID Days lived Disease findings Diagnosis 
887 33 leukocytosis, monocytosis, blasts in PB and BM myeloid leukemia 
846 36 anemia, blasts in PB and BM, hypocellular marrow myeloid leukemia 
204 139 anemia, splenomegaly, cd11b+ liver and spleen infiltrates myeloid leukemia 
233 420 anemia, monocytosis, liver and spleen infiltrates, disease 
transplantable to irradiated recipients 
myeloid leukemia 
99 670 pancytopenia, splenomegaly, blasts in PB and cytospin, Gr1+cd11b+ 
cells in PB, disease transplantable to irradiated recipients 
myeloid leukemia 
504 465 anemia, monocytosis, splenomegaly, liver and spleen infiltrates, blasts in 
PB, hypocellular marrow, disease transplantable to irradiated recipients 
myeloid leukemia 
(sub- classification: 
histiocytic sarcoma) 
251 44 pancytopenia, blasts in PB unknown* 
637 42 thrombocytopenia, monocytosis, blasts in PB unknown* 
704 42 pancytopenia, hypocellular marrow, blasts in PB, increased B220 
positivity in BM and PB 
lymphoid leukemia 
415 506 CD3low+B220low+ blasts in PB & cytospin, hypocellular marrow; 
disease transplanted to irradiated recipients 
lymphoid leukemia 
430 548 pancytopenia, hypocellular marrow, abdominal hematopoietic 
mass, splenomegaly, CD3+ B220+ liver and spleen infiltrates 
lymphoid leukemia 
145 622 pancytopenia, B220+ liver & spleen infiltrates, numerous mitotic 
figures in BM histology 
lymphoid leukemia 
420 599 CD3+ hematopoietic abdominal mass lymphoid leukemia/lymphoma 
164 730 CD3+ B220+ hematopoietic abdominal mass, liver infiltrates lymphoid leukemia/lymphoma 
2
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Table 1. Summary of individual cases of Fancc-/-; Mad2+/- moribund mice with 
hematologic malignancies. PB = peripheral blood; BM= bone marrow. *Designation of 
unknown was given to cases in which leukemia was suspected, but Bethesda criteria for 
leukemia was not able to be fully met due to lack of evidence or decomposed tissues. 
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Figure 6. Myeloid leukemias in Fancc-/-; Mad2+/- mice. (A) Splenomegaly in the 
moribund Fancc-/-; Mad2+/- mice. Error bars represent SEM and the p value was 
obtained by student’s t test, with n ≥ 5 mice/genotype. (B) Representative images of 
myeloid blasts in peripheral blood of Fancc-/-; Mad2+/- mice (right) compared with a wt 
monocyte. Blasts were defined according to the Bethesda criteria (80). Peripheral blood 
flow of moribund Fancc-/-; Mad2+/- mice showed a high percentage of WBCs positive 
for myeloid markers Gr1 and Mac1 (C, D). Quantification represents at least 5 mice per 
group. (E) Histological sections of Fancc-/-; Mad2+/- mice (right) compared with wt 
(left). Leukemic infiltrates on liver H & E (top, yellow lines outline infiltrates), ckit+ IHC 
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staining in bone marrow H & E (middle), and Mac1+ staining on IHC of spleen (bottom) 
are prominent features of the Fancc-/-; Mad2+/- myeloid leukemias. 
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Figure 7. Summary of criteria used for diagnosis of murine hematologic illnesses. 
Criteria were adapted from the Bethesda proposals for classification of nonlymphoid 
hematopoietic neoplasms in mice (80), and the Bethesda proposals for the classification 
of lymphoid neoplasms in mice (81). 
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Figure 8. Leukemia from Fancc-/-;Mad2+/- donor resulted in disease in transplant 
recipients. One million LDMNCs from Fancc-/-;Mad2+/- #504 were transplanted into 
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two lethally irradiated recipients, both of which died of disease. Forward and side scatter 
flow profiles (A) of WBCs from peripheral blood depict a high FSC/SSC population, 
consistent with myeloid cells, that predominates in the 504 donor and recipient mice. (B) 
WBCs from bone marrow of both 504 donor and 504 recipients are predominately 
Gr1+Mac1+. (C) Bone marrow H & E sections from both 504 donor and recipient show a 
uniform myeloid population, as compared with the mixture of heterogeneous cell types 
seen in wt marrow section. (D) Liver infiltrates are evident in both 504 donor and 
recipient mice. 
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Table 2. Summary of Fancc-/-;Mad2+/- leukemia transplants. Transplantation of 
leukemic bone marrow from moribund Fancc-/-;Mad2+/- donor mice resulted in disease 
in transplant recipients. Lethally irradiated recipient mice were transplanted with donor 
cells as well as a fraction of wt competitor cells to ensure recipient survival post- 
transplant. 
Transplantation of leukemias from Fancc-/-;Mad2+/- mice to healthy recipients 
 
Donor mouse 
genotype 
transplant 
donor:competitor 
ratio 
recipient 
death due 
to 
leukemia 
incidence of 
leukemia at 
end of study 
 
disease 
classification 
Wt # 891 1:1 0/3 0/3 N/A 
Wt # 726 1:1 0/2 0/2 N/A 
Wt # 565 1.4:1 0/3 0/3 N/A 
Fancc-/-;Mad2+/- 
#504 
1:1 
2/2 2/2 myeloid 
leukemia 
Fancc-/-;Mad2+/- 
#233 
1:1 
2/5 5/5 myeloid 
leukemia 
Fancc-/-;Mad2+/- 
#99 
1.4:1 
1/3 3/3 myeloid 
leukemia 
Fancc-/-;Mad2+/- 
#415 
1.4:1 
1/2 2/2 lymphoid 
leukemia 
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Figure 9. Lymphoid leukemia/lymphomas in Fancc-/-; Mad2+/- mice. Splenomegaly 
 
(A) and increased mitotic figures (yellow arrows) in splenic germinal centers (B) of 
Fancc-/-; Mad2+/- mice with follicular lymphomas. (C) Lymphoid infiltrate (yellow 
arrow) into liver (left) that stains positive for B cell marker B220 by IHC (right) in 
moribund Fancc-/-; Mad2+/- mouse. (D) Abdominal lymphoid mass (red dashed line) 
surrounding intestine of Fancc-/-;Mad2+/- mouse. (E) H & E (left) and IHC (right) of 
abdominal mass reveals CD3+ and B220+ cell populations. (F) Flow cytometry of WBCs 
from peripheral blood of a moribund Fancc-/-; Mad2+/- mouse (right), showing an 
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aberrant circulating population of CD3low+B220low+ cells, compared with a wt flow 
profile (left). 
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Figure 10. Normal hematopoiesis in Fancc-/-; Mad2+/- mice until moribund state. 
 
(A) Percentage of WBCs expressing lineage specific surface markers from peripheral 
blood. 2-3 month old healthy mice of all genotypes were compared with moribund 
Fancc-/-; Mad2+/- mice at time of death, n≥5mice/group. (B) Levels of WBCs, 
hemoglobin, and platelets obtained from complete blood counts of 2-3 month old healthy 
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mice or moribund mice at time of death, n≥8 mice/group. (C) Total number of colonies 
grown in methylcellulose colony forming assays and (D) bone marrow cellularity of 
healthy 16 week old mice and moribund Fancc-/-; Mad2+/- mice, n≥9 mice/group. 
Statistics represent One-way ANOVA with Dunnett’s multiple comparisons test, *p ≤ 
0.05, *** p ≤ 0.001, **** p ≤ 0.0001. 
 
 
 
 
 
 
37  
 
 
 
36 
 
 
 
 
Figure 11. Competitive repopulation transplant experiment highlights malignant 
potential of Fancc-/-; Mad2+/- HSCs. (A) Transplant schema for competitive 
repopulation studies. (B) Peripheral blood chimerism in transplant recipients at 3 months 
post transplant. Error bars represent standard error of the mean, and statistics were 
obtained from Bartlett’s test for differences in standard deviations. Representative flow 
profiles (C) and quantification of myeloid populations (D) in PB gated on CD45.2+, 1 
year post-transplant. Graph represents at least 7 mice/group. (E) Table depicting 
incidence of myelodysplasia in transplant recipients 1 year after transplant. Fisher’s exact 
test was used for statistics, with p<0.01 considered significant. (F) Colony forming ability 
of CD45.2+ cells harvested from primary recipients one-year post transplant. 20,000 
LDMNCs were plated on methylcellulose in triplicate (n = 4 recipient mice/group). Error 
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bars represent SEM, and analysis was done via one-way ANOVA with Bonferroni’s post 
hoc test for both (D) and (F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
39  
 
 
 
38 
Fancc-/-;Mad2+/- mice display heightened genomic instability 
 
Due to genetic disruption of two SAC genes in Fancc-/-; Mad2+/- mice, we expected to 
observe a heighted genomic instability in this genotype to accompany the cancer 
predisposition phenotype. Spectral karyotyping of bone marrow cells from leukemic 
Fancc-/-;Mad2+/- mice revealed whole chromosome gains and losses (Fig. 12A). We 
also counted chromosome numbers in metaphase spreads prepared from cultured 
LDMNCs from healthy age-matched mice of all genotypes, and found a heightened 
incidence of aneuploidy in the Fancc-/-;Mad2+/- group (Fig. 12B-C). We were also able 
to identify exacerbated genomic instability in the Fancc-/-; Mad2+/- erythroid lineage 
using a pre-established red blood cell (RBC) micronucleation assay (44). Via flow 
cytometry, we identified an increased percentage of genomically unstable micronucleated 
RBCs (defined as CD71-, propidium iodide+) in the peripheral blood of Fancc-/-; 
Mad2+/- mice at 12 months of age compared to age-matched littermates of control 
genotypes (Fig. 13A-B). Imaging of Geisma-stained cytospins also revealed similar 
findings of a greater percentage of multinucleated bone marrow cells in the Fancc-/-; 
Mad2+/- mice (Fig. 13C-D). 
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Figure 12. Fancc-/-; Mad2+/- hematopoietic cells are genomically unstable. (A) 
Representative images from spectral karyotyping of wt and leukemic Fancc-/-;Mad2+/- 
bone marrow cells. At least 11 cells/genotype were evaluated for cytogenetic 
abnormalities. (B) Example images of individual metaphase spreads made from bone 
marrow cells from age-matched healthy mice captured at 100x on a Deltavision 
deconvolution miscroscope. (C) Quantification of chromosome number per individual 
spread (n = 150 spreads/genotype), with statistical significance calculated by Fisher’s 
exact test and Bonferroni post-hoc analysis. Murine cells have 40 chromosomes. 
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Figure 13. Fancc-/-; Mad2+/- hematopoietic cells display micronucleation and 
multinucleation. Flow profiles (A) from a red blood cell (RBC) micronucleation assay, 
identifying mature micronucleated RBCs as CD71-, propidium iodide+. Quantification of 
percentage of micronucleated cells in PB of mice shown as fold difference compared to 
controls (B). Data represents at least 9 age-matched animals/genotype with statistical 
analysis done via Fisher’s exact test. (C) Representative images of multinucleated 
LDMNCs from healthy Fancc-/-; Mad2+/- mice and (D) quantification of percentage of 
multinucleated LDMNCs on Giesma-stained bone marrow cytospins. At least 800 
cells/genotype were counted, and statistical significance was determined by Fisher’s 
exact test. ***p ≤ 0.0001, ** p ≤ 0.01. 
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Heightened genomic instability in Fancc-/-; Mad2+/- animals is due to exacerbated 
SAC dysfunction 
Finally, to demonstrate that the heightened genomic instability in the Fancc-/-; Mad2+/- 
mice was indeed due to exacerbated SAC impairment, we isolated ckit+ cells from the 
bone marrow of Fancc-/-; Mad2+/- and control mice, pulsed them with EdU and cultured 
them in the presence of 100ng/ml nocodazole for 12 hours. We then quantified the 
percentage of mitotic cells (EdU+, pHH3+ staining) and multinucleated cells 
(distinguished by nuclear morphology and EdU+, pHH3- staining) in each group. While 
the majority of wt ckit+ cells arrested in mitosis upon nocodazole treatment, the Fancc-/-; 
Mad2+/- cells failed to arrest and became multinucleated, demonstrating a heightened 
SAC impairment than that of both Fancc-/- or Mad2+/- groups with a single SAC gene 
deficiency (Fig. 14A-C). Phase-contrast live imaging of MEFs treated with 2μM taxol 
revealed a shorter time of mitotic arrest in the Fancc-/-; Mad2+/- genotype compared to 
wt and single mutant control cells (Fig. 14D-E), further demonstrating impaired SAC 
function in this genotype. 
 
 
After determining the central role of SAC dysfunction in our model, and our knowledge 
that FA-associated genomic instability is driven by additional factors besides mitotic 
abnormalities, we next explored the DNA damage repair status of the Fancc-/-; Mad2+/- 
intercross. In methylcellulose progenitor assays with increasing doses of the crosslinking 
agent mitomycin C, Fancc-/-; Mad2+/- bone marrow progenitors demonstrated increased 
hypersensitivity to MMC similar to that of Fancc-/- mice (Fig. 15A-B). We also 
performed a chromosome breakage test by culturing LDMNCs of each genotype in 50nM 
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MMC for 48 hours, and then identifying chromosome breaks by microscopy of 
metaphase spreads. As expected, Fancc-/- cells displayed an increased frequency of 
breaks that was importantly not further exacerbated in the Fancc-/-; Mad2+/- cells (Fig. 
15C). These studies eliminate the possibility of heightened DNA damage as a 
contributing factor to the increased aneuploidy and cancer predisposition of our 
intercrossed model. 
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Figure 14. Genomic instability in Fancc-/-; Mad2+/- mice is due to exacerbated SAC 
dysfunction. (A) Example images of cell cycle phases observed in ckit+ bone marrow 
fraction after EdU pulse and incubation with 100ng/ml nocodazole for 12 hours. 
Percentage of mitotic cells (B) and multinucleated cells (C) per genotype were quantified. 
At least 200 cells/genotype were imaged, and Fisher’s exact test was used for statistics. 
(D) Low passage mouse embryonic fibroblasts (MEFs) of each genotype were treated 
with 2µM taxol and imaged on a Nikon Biostation phase contrast live imaging 
microscope, which captured pictures at 2 minute intervals for 24 hours. Time in mitosis 
(defined as the onset of nuclear envelope breakdown until the time the nuclear envelope 
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reforms) was recorded for at least 90 cells/genotype, and analyzed by one-way ANOVA 
and Tukey’s post-hoc multiple comparisons test. (E) Time lapse frames (minutes) 
demonstrating mitotic arrest of a wt cell in taxol (top panel) as compared with the SAC 
breakthrough and shortened mitosis of a Fancc-/-; Mad2+/- cell (bottom panel). 
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Figure 15. Mad2 heterozygosity does not worsen the DNA damage repair (DDR) 
defect upon loss of Fancc. Hematopoietic colony forming assays were performed in 
varying doses of MMC, using LDMNCs from n =3 age-matched mice/genotype. (A) 
Fancc-/- and Fancc-/-; Mad2+/- progenitors formed smaller colonies in MMC and (B) 
fewer total colonies n a dose-dependent manner. Two-way ANOVA was performed, and 
statistics represent comparisons within genotypes compared to the control 0nM MMC 
treated group. (C) Chromosome breakage test was performed by preparing metaphase 
spreads from bone marrow cells treated with 50nM MMC for 48 hours. The number of 
breaks/cell (red asterisks) was quantified on the deconvolution scope, and demonstrate 
that both Fancc-/- and Fancc-/-; Mad2+/- cells have similar chromosome breakage 
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profiles in MMC. At least 100 cells/genotype were analyzed, and Fisher’s exact test was 
used to determine significance. ****p ≤ 0.0001. 
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DISCUSSION 
 
We have generated a novel FA-SAC model via the intercross of Fancc-/- and Mad2+/- 
mice. Fancc-/-;Mad2+/- mice are predisposed to developing hematologic malignancies 
secondary to heightened aneuploidy and exacerbated SAC dysfunction. The majority of 
the malignancies seen in these mice are myeloid leukemia cases, faithfully recapitulating 
the common cancer seen in FA patients. 
 
 
SAC impairment contributes to tumorigenesis in our mouse model, in which one of the 
core FA genes, Fancc, is deficient. There is also in vivo evidence that Brca2/Fancd1, 
regulates the SAC by promoting BubR1 acetylation in mitosis to protect genomic 
integrity (77, 78). Recently Vasanthakumar, et al generated a conditional Brca1/Fancs 
knock out mouse model that develops spontaneous BMF and displays cytogenetic 
abnormalities (61). Taken together, these models demonstrate the importance of FA 
signaling in regulating the SAC to prevent tumorigenesis. 
 
 
Our model displays aneuploidy due to SAC dysfunction, and subsequent cancer 
predisposition. We know that aneuploidy can lead to tumorigenesis by unequal 
distribution of genetic material, potentially yielding a proliferative and evolutionary 
advantage to a daughter cell (50). Another mechanism by which aneuploidy can promote 
tumorigenesis is via chromothripsis, whereby one chromosome gets pulverized and 
undergoes massive structural rearrangements. This occurs when a micronucleus, formed 
from a missegregated lagging chromosome, undergoes DNA damage as it enters the 
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subsequent mitosis without having finished the previous replication (83). This 
catastrophic event can either compromise or heighten cell fitness. Identifying the 
micronucleus itself as a source of genomic instability in aneuploidy cells is a exciting 
concept that may be relevant to understanding genomic instability in FA, given that 
micronucleation and aneuploidy are hallmark FA features (84, 85). It is possible that this 
process is occurring in our FA-SAC model, an idea that will need further investigation. 
 
 
Like our model, many other genetic models of aneuploidy display heightened cancer 
incidence (78, 86, 87). However, there are also mouse models of aneuploidy that are 
tumor suppressive (88, 89). Rationale behind this apparent contradiction is based on the 
difference of the rate of chromosome missegregation in different models. A lower rate of 
missegregation (one or two chromosomes per division) seems to promote cancer, while a 
CIN rate that exceeds a certain threshold (more than five chromosomes per division) 
rather leads to cell death and has a tumor suppressive effect (59, 88). Unsurprisingly then, 
complete loss of certain SAC genes, such as Mad2 and BubR1, are embryonic lethal (82). 
This dichotomy has sparked the idea of accelerating chromosome missegregation as a 
therapeutic strategy to target cancers with low rates of chromosome missegregation. For 
example, inhibition of CENP-E, a mitotic motor protein that controls chromosome 
alignment, in SAC-impaired cancer cells was shown to promote p53 activation and 
aneuploidy, which subsequently contributed to replication stress-mediated DSBs and 
proteotoxic stress (90). Given the FA pathway’s central role in protecting genomic 
integrity by regulating the SAC, DNA damage repair, and genotoxic stress, utilization of 
such anti-mitotic therapies in FA-deficient tumors could be highly specific and effective 
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at halting tumor growth. Our FA-SAC model, which genetically induces chromosome 
missegregration that is tumor-promoting, may be a platform to test this strategy. 
 
 
Our studies additionally demonstrate that deficiency of these two SAC regulators Fancc 
and Mad2 cooperate to disrupt hematopoiesis. We observed MDS-post transplant and 
functional impairment in HSCs after transplant of Fancc-/-; Mad2+/- LDMNCs. In 
addition to its role at the SAC, Mad2 associates with c-kit, a tyrosine kinase receptor in 
immature hematopoietic cells, and Mad2+/- immature hematopoietic cells cycle less 
frequently than expected (91). Many additional SAC-associated proteins are known to be 
required for normal hematopoiesis, particularly in regulating the maturation of 
megakaryocytes. Interestingly, mature megakaryocytes become polyploid by the process 
of endomitosis, in which nuclear division occurs followed by failed cytokinesis (92). 
Heterozygosity of the mitotic checkpoint kinase Bubr1 causes decreased pro-platelet 
forming ability of megakaryocytes (93). Fanca-/- mice have diminished platelet 
formation and decreased proliferation of megakaryocyte progenitors, demonstrating that 
Fanca is required for normal megakaryocyte differentiation (94). Also progression of the 
metaphase-to-anaphase transition relies on proteasome-dependent degradation, and 
pharmacologic inhibition of the proteasome blocks proplatelet formation (95). These 
studies, in concert with our observations in our FA-SAC model, support the importance 
of regulated SAC function in preserving normal hematopoiesis. 
 
 
The current understanding of the pathogenesis of BMF and leukemia in FA relies on our 
understanding of how loss of FA signaling, the complex regulatory system protecting 
51  
 
 
 
50 
genome integrity, affects the HSC. HSCs are a typically quiescent cell in the bone 
marrow, but when presented with physiological stress, can be provoked to exit their 
normal quiescent state. This exit from senescence provokes DNA-damage-induced 
attrition of the cycling HSCs, and subsequent p53 activation resulting in a BMF-like state 
(96), which given our findings, is likely in part due to compromised mitosis. 
Additionally, dividing HSCs that undergo erroneous mitosis increase the likelihood of 
clonal evolution, a phenomenon that has been seen in our model (Fig. 11) and after ex- 
vivo culture and transplant of Fancc-/- HSCs (97). Thus the impaired SAC mitotic 
function of FA-deficient cells likely cooperates with lack of DNA repair ability and an 
environment of genotoxic stress to create the perfect storm of disease progression. 
 
 
Our findings highlight the tumor suppressive role of Fancc in maintaining the SAC to 
prevent aneuploidy and cancer development in vivo. We also know from our model that 
Fancc and Mad2 act cooperatively to regulate the SAC. However, the signaling 
mechanism by which FANCC regulates the SAC during mitosis is still unclear. Kupfer et 
al has previously demonstrated that FANCC binds cyclin-dependent kinase 1 (CDK1), 
the mitotic checkpoint kinase whose activity must be silenced for mitotic exit (98). 
Additionally, FANCC is required for proper mitotic spindle formation and 
phosphorylation of stathmin-1, a regulator of microtubule dynamics (99). Interestingly, it 
was recently discovered that FANCC binds the E3 ubiquitin ligase Parkin (38), a protein 
that complexes with cdc20 to control mitotic progression (100). More work is needed to 
better understand the role of FANCC in the SAC and throughout mitosis. 
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FUTURE DIRECTIONS 
 
We have characterized a novel FA-SAC whole-body transgenic model that develops 
hematopoietic-centered malignancies. Genetic disruption of Mad2 and Fancc results in 
increased random aneuploidy and heightened risk for cancer. Although many of these 
mice spontaneously developed leukemias at a young age (<6 months), others did not 
succumb to malignancy until much later in life (18-24 months). We also did not observe 
any animals develop spontaneous BMF, though myelodysplasia was prevalent. 
We would next like to pharmacologically challenge these FA-SAC animals to see if we 
can elicit a more robust phenotype in our model. We know that Fancc-/-; Mad2+/- 
hematopoietic cells are hypersensitive to taxol, and dosing these animals may elicit a 
BMF-like phenotype. On the other hand, we hypothesize that exposing the Fancc-/- 
;Mad2+/- animals to granulocyte colony stimulating factor (G-CSF), would increase the 
fraction of cycling hematopoietic cells, and given their impaired mitosis, accelerate the 
development of leukemias. 
 
 
We are also expanding our genetic studies to include intercrossing Fanca-/- and Mad2+/- 
mice. We will compare the phenotype of these mice with our FA-SAC model to 
understand whether Fanca and Fancc, two core complex FA genes, act similarly to 
regulate the SAC. 
 
 
Our ultimate goal with the FA-SAC model is to begin preclinical studies to probe the 
usefulness of antimitotic therapies for FA-related cancers. Direct treatment of leukemias 
53  
 
 
 
52 
in Fancc-/-; Mad2+/- mice would likely be highly toxic, as these mice are whole-body 
transgenics. Instead we plan to transplant leukemia cells from Fancc-/-; Mad2+/- mice 
into irradiated congenic wt recipients, and then subsequently attempt to slow disease 
progression in recipients with antimitotic therapy such as taxol. 
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                   CHAPTER TWO 
 
                  INTRODUCTION 
 
Spindle assembly checkpoint signaling 
 
The spindle assembly checkpoint senses the attachment state of kinetochores, and 
regulates the metaphase-to-anaphase transition to ensure proper chromosome segregation 
(101). The checkpoint inhibits the anaphase-promoting complex (APC/C), a mitotic 
ubiquitin ligase that facilitates the onset of anaphase. Upon binding to its activator 
CDC20, the APC/C promotes anaphase onset by degrading its substrates cyclin B1, the 
binding partner for the mitotic kinase cdk1, and securin, which blocks the protease 
separase to maintain sister chromatid cohesion (102). Upon sensing an unattached 
kinetochore, a hierarchy of SAC proteins is recruited to the kinetochore to activate the 
SAC, culminating in the recruitment of the proteins Mad1 and Mad2. Kinetochore 
recruitment of Mad2 prompts a change in its conformation from the free “open” 
conformation to its “closed” form (103). The closed conformation of Mad2 enables the 
formation of the mitotic checkpoint complex (MMC), consisting of the proteins Mad2, 
Bubr1, and Bub3 (104). The MCC sequesters CDC20, thus keeping the APC/C from 
being activated (104), and delaying anaphase onset until all kinetochores are properly 
attached to the mitotic spindle (Fig. 16). 
 
 
The SAC can be activated through independent mechanisms of recruitment of 
Mad1/Mad2 to the KT (Fig. 17). When a KT is unattached to the spindle, Mad1/Mad2 
KT recruitment occurs through two distinct signaling cascades, the KBB axis and the 
RZZ axis. Phosphorylation of the KT protein KNL1 recruits Bub1 and Bub3 (105), 
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forming the KBB complex that can recruit Mad1:Mad2. Additionally, unattached KTs 
recruit Zw10, Rod, and Zwilch—the RZZ complex—which also prompts Mad1:Mad2 
localization to the KT (106, 107). The recent finding that unattached KTs can still recruit 
the RZZ and activate the SAC in the absence of KNL1 demonstrated that the KBB and 
RZZ axes independently recruit Mad1:Mad2 to the KT (108). Importantly, the strength of 
the SAC signal is based on the amount of Mad2 at the KT (109). 
 
 
RZZ recruitment to the KT has been extensively studied. Stable KT localization of 
ZW10, a member of the RZZ complex, depends on its interaction with Zwint (110). 
This interaction requires Zwint phosphorylation by Aurora B kinase (111). Intriguingly, a 
pervious yeast two-hybrid screen identified Zwint as a potential interactor with Fancc, 
but did not validate the hit (112). 
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Figure 16. The SAC delays anaphase onset through MCC-mediated inhibition of the 
APC/C. 
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Figure 17. The KBB and RZZ pathways independently recruit Mad1/Mad2 to the 
KT to activate the SAC. 
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FANCC signaling at the SAC 
 
Although it is well-established that FANCC regulates the SAC (43), little is known about 
the mechanism by which this occurs. Interestingly, Kupfer et al noted that FANCC binds 
CDK1 during the G2/M phase of the cell cycle (98), a finding that was highlighted years 
before any mitotic functions of FANCC were known. CDK1 is a mitotic kinase that is 
both a target and regulator of SAC response (101, 113). Thus we set out to further 
elucidate the CDK1-FANCC interaction at the SAC, and knowing the lack of epistasis 
between FANCC and MAD2 (see CHAPTER ONE), we hypothesized that FANCC 
signaling, though a possible interaction with Zwint, regulates the RZZ axis of the SAC. 
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MATERIALS AND METHODS 
 
 
Cell culture 
 
Patient fibroblast cell lines were cultured in DMEM supplemented with 15% FBS, 1% 
Penicillin-Streptomycin, 1% L-glutamine, and 1% Sodium pyruvate, and maintained in 
37oC, 5% O2 incubators. HeLa cell lines were fed with 10% FBS and 1% Penicillin- 
Streptomycin in DMEM and cultured in 37oC incubators. 
 
 
Statistical analysis 
 
Statistics were performed using Graph Pad Prism 6.0. Specific tests used and levels of 
significance are noted in the figure legends. 
 
 
Immunofluorescence 
 
Cells plated on coverslips were extracted for 30 seconds in 0.2% Triton diluted in PBS, 
and then fixed in 4% paraformaldehyde for 15 minutes at RT. Alternatively, for 
antibodies that did not need extraction, cells were directly fixed in 4% paraformaldehyde. 
Coverslips were then blocked in 0.2% Triton, 5% BSA solution in PBS for 1 hour. 
Coverslips were then incubated in primary antibody (diluted in PBS or 1% BSA-PBS, 
depending on antibody) overnight at 4oC. Cells were washed three times with PBS, and 
then incubated in secondary antibody (Thermo Alexa 488 or 594 diluted 1:2000 in PBS 
or 1% BSA-PBS) at RT in the dark for 45 minutes. Cells were again washed in PBS, and 
mounted with ProLong Diamond Antifade mountant with Dapi (Thermo Fisher). Images 
were taken on a Deltavision deconvolution microscope, as described in CHAPTER 
ONE.
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Primary antibodies 
 
The following antibodies were used for western: anti-β-actin (Sigma); anti-FANCC 
(Santa Cruz, sc18110, 1:250); anti-Zwint (Abcam, ab168501, 1:1000); anti-FANCC 
(Abcam ab5065, 1:1000). 
For immunofluorescence: anti-FANCC (ab97575, Abcam, 1:200); anti-CENPA 
(ab13939, Abcam 1:100); anti-Zwint (Abcam ab71982, 1:100); anti-Zwint (Abcam, 
ab168501, 1:100); anti-ZW10 (Abcam, ab21582, 1:100). 
For immunoprecipitation: anti-FANCC (Santa Cruz, sc18110), anti-Zwint (Abcam 
ab71982). 
 
 
Immunoblotting 
 
Protein lysates were harvested using M-PER lysis buffer (Thermo Fisher) supplemented 
with protease inhibitor (Complete mini, Sigma) and phosphatase inhibitor cocktails 
(Pierce). Cell debris was pelleted for 5 minutes at 13,000rpm at 4oC, and the supernatant 
saved for BCA protein quantification. After addition of SDS, lysates were boiled at 95oC 
for 5 minutes, and loaded onto 4-12% Bis-Tris gradient gels (Thermo Fisher). Gels were 
run at 100-120V for 2 hours with MES running buffer. Proteins were then transferred 
onto nitrocellulose membrane. The membrane was blocked for one hour in Odyssey 
blocking buffer (Licor) and incubated in primary antibody diluted in blocking buffer 
overnight at 4oC. After washing in PBS-T, the blot was incubated in fluorescent 
secondary antibody (Licor) diluted 1:5000 in blocking buffer for one hour in the dark, 
washed again with PBS-T, and developed using the Licor Odyssey CLx Imaging system.
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Immunoprecipitation 
 
For immunoprecipitation studies, 1mg protein was harvested from HeLa cells using 
MPER lysis buffer. The immunoprecipitation procedure was performed according to 
manufacturer instructions of the Thermo Fisher Crosslink IP Kit. Pulled-down protein 
eluted from the crosslinked column was denatured by SDS addition and developed by 
western blotting described above. Antibodies used for pulldown and western were 
derived from different host species. 
 
 
Immunofluorescence quantification of kinetochore recruitment 
 
Deconvolved image files were analyzed in Imaris software (version 7.7.1, Bitplane), 
using the spots function in surpass view mode. The region of interest was determined 
based on DAPI signal (DNA). The kinetochore signal (based on CENPA or ZWINT 
staining) was defined with xy diameter (0.3 µm) and ellipsoid size (0.6 µm) parameters. 
To eliminate background signal, the background subtraction Imaris function was used 
and a fluorescence quality threshold was set manually. The spots function then calculated 
the number of kinetochores with positive signal for the protein of interest and maximum 
intensity of signal per kinetochore. At least 300 kinetochores/group were used for 
analysis, and statistics were obtained using a student’s t-test (for maximum intensity of 
signal at kinetochore) and a Fisher’s exact test (for percentage of kinetochores with 
positive signal). 
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Pharmacologic inhibition of CDK1 
 
For mitotic synchronization, HeLa cells were treated with 9µM R03306 (Sigma) for 22 
hours, and then washed and released from G2 into mitosis for 30 minutes. After 30 
minutes, 3 µM R03306 was added for an additional 30 minutes before harvesting cells. 
At this low dose, R03306 specifically inhibits CDK1, yet cells are still able to enter 
mitosis(114), so inhibition of CDK1 can be studied in a mitotic population. Cells were 
then stained with antibodies directed against either FANCC or ZW10 as described in 
above. 
 
 
In vitro kinase assay 
 
In vitro kinase assays were performed by incubating varying amounts of recombinant 
human FANCC protein (Abnova) with 1.25 U recombinant CDC2/cyclin B kinase (New 
England Biolabs) and 2ug histone H1 (CDC2 substrate) in kinase buffer (50 mM Tris- 
HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 40 mM β-glycerophosphate, 20 
mM p-nitrophenylphosphate, 0.1 mM sodium vanadate, and 0.01% Brij 35) for 30 min in 
the presence of radioactive [P32]γ-ATP (1 µCi). Reactions were terminated by running 
SDS-page and analyzed by autoradiography. 
 
 
Protein phosphorylation site prediction 
 
FANCC FASTA sequence was inputted into various online phosphorylation prediction 
sites: NetPhos2.0 (115), PhosphoNet (www.phosphonet.ca), and NetPhosK (116). 
Selected putative phosphorylation sites had a score > 0.90 (the closer to 1 indicates 
higher confidence of prediction), and were located within the known CDK1 binding 
region (98). 
63  
 
 
 
62 
Plasmids & site-directed mutagenesis 
 
C-terminal Myc-DDK-tagged FANCC cDNA in a PCMV6 entry vector was purchased 
from Origene. Site directed mutagenesis of FANCC was completed using the 
QuickChange XL site-directed mutagenesis kit (Agilent) and validated by Sanger 
sequencing. Mutagenesis and sequencing primers were generated using the 
NEBaseChanger website. Mutagenesis primers to generate S345A were: 5’- 
Cctactttccttacactgctccatctcttg-3’ (forward) and 5’- Caagagatggagcagtgtaaggaaag-3’ 
(reverse). Mutagenesis primers for S540A were: 5’- cgtcttggcattgaaggccctagatcag -3’ 
(forward) and 5’- tttctgatctagggccttcaatgccaagac-3’ (reverse). S543A was created using: 
5- gcattgaaagccctagagcagaaaaac-3’ (forward) and 5’- tcgggccagtttttctgctctagggctttc-3’ 
(reverse). The following sequencing primers used were designed to cover the ORF of 
FANCC with overlapping reads: 5’-gtttagtgaaccgtcagaattttg-3’; 5’-gtaaacgaggccattttgc- 
3’; 5’-gctgggccacctcctggc-3’; 5-ctgagaggctgctgcttc-3’; 5’-gttcaggaaacagctatgaccg-3’; 5’- 
gccagaggcagactacag-3’. 
 
 
Transfection 
 
HeLa cells were transfected using the X-tremeGENE HP DNA transfection reagent 
(Roche) according to the manufacturer’s protocol. 
 
 
Virus generation & titration 
 
To generate a virus backbone with desired neomycin selection, we cloned the SV40-Neo 
SV40-Neor/Kanr-PolyA cassette from pCMV6-Entry-FANCC-DDK vector (Origene) to 
64  
 
 
 
63 
pLenti-C-Myc-DDK vector (Origene). The SV40-Neor/Kanr-PolyA cassette was cut out 
from pCMV6-Entry-FANCC-DDK vector by BspHI (NEB) digestion, and pLenti-C- 
Myc-DDK vector was linearized by XbaI (NEB) digestion. Both the SV40-Neor/Kanr- 
PolyA fragment and the linearized pLenti-C-Myc-DDK backbone were blunted by DNA 
polymerase Klenow large fragment (NEB) and ligated by T4 DNA ligase (NEB). The 
presence and orientation of the SV40-Neor/Kanr-PolyA fragment in the pLenti-C-Myc- 
DDK vector was confirmed by SfiI (NEB) digestion. We then cloned the FANCC (and 
mutant versions described above) from the pCMV6-backbone into the newly created 
pLenti-C-Myc-DDK-NeorKanr vector. The FANCC-DDK fragment was cut out from 
pCMV6-Entry-FANCC-DDK vector by SgfI and MluI digestion and inserted into pLenti- 
C-Myc-DDK-NeorKanr vector linearized by the same SgfI and MluI digestion. The final 
product is a lenti vector encoding FANCC-DDK and NeorKanr. 
 
 
To generate virus, 293T cells (at 70% confluence) were transfected with 10ug of 
FANCC-DDK- NeorKanr –lentiviral vector (containing wildtype FANCC or site 
mutants), 5ug of helper plamis (pCD-NL/BH) and 1 ug foamyviral envelope containing 
plasmid (pcoPE01) in 6ml DMEM supplemented with 10% FBS and 0.0075mg/ml 
polyethyleneimine. After overnight incubation at 37oC, media was replaced with DMEM 
supplemented with 10% FBS, 1% P/S, 1% glutamine, and 2% sodium bicarbonate, and 
incubated for an additional 24 hours. Virus was then concentrated by filtering through a 
polyethersulfone membrane (mesh size 0.45um) and centrifuging at 10,000rpm for 2 
hours at 4 oC in 50ml conical tube. The viral pellet was resuspended in 1ml fresh DMEM, 
and utilized or stored in aliquots at -80oC. Titration of the virus was determined by 
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seeding 50,000 HT1080 cells/ well of 6 well plate. Cells were serially transduced and 
percent GFP positivity via flow cytometry was used to calculate titer. 
 
 
For transduction, virus was added to cell culture overnight, and media was replaced the 
next morning. 24 hours post-transduction, fibroblasts were selected with 0.4mg/ml G418 
(Geneticin, Thermo fisher) for 5 days. 
 
 
Sequencing of primary patient fibroblasts 
 
Genomic DNA was isolated from primary cell pellet (BKBK cells) incubated in cell lysis 
buffer with Proteinase K at 56 oC overnight. After addition of protein precipitation 
solution, the sample was centrifuged at 13000rpm for 10 min, and resuspended in cold 
isopropanol at -20 oC for 20 minutes. The precipitated DNA was then washed with 70% 
ethanol, and resuspended in water. Multiple primer sets (forward and reverse) were 
designed using SnapGene version 3.3 to flank each of the 14 exons of FANCC. Primers 
were used for both amplification of the exon from genomic DNA as well as Sanger 
sequencing. Primer sequences used were as follows: 
 
 
 
exon Primer set (written 5’ to 3’) 
1 F:   gacttctagcctaatgatagtatcatg 
R:   gtgtcatgtaacaatacagc 
2 F:   gcctttactgactattaagtatgagtag 
R:   gtagatatttaaatcatctgggag 
3 F:   gaccacacaagagttaagtg 
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 R:  ggaattcacagtcaagc 
4 F:   catgtacaaataaattgtaggcattg 
R:   gttaaacatctcttctggaggactg 
5 F:   gacctgtctattgttcattgc 
 
R:  ctcaccaatttgctatgtattccac 
6 F:   gacactgaaacagcaatggtag 
R:   gctgtcgtacagtctttccaac 
7 F:   cttccatcactagacatttgcttattc 
R:   gcatgctccaaggatg 
8 F:  caggcacacttcagtagaac 
R:   gcctaactcaattctgtgtttc 
9 F:   gtacagagtatgcaagcctg 
R:   catgacagagttctcagac 
10 F:   gtgaagtagaactcataaagacatc 
R:   gtgatcacaactgggaag 
11 F:   gatgttcaactctgtgtgacatggac 
R : gatggtcccagaccag 
12 F:  cagtgcctgtcctcactg 
R:  gcctgcaggttgccatgac 
13 F:   gactacattctgttgagaac 
 
R:   ctgcgatggaaagaaatgtacg 
14 F:   gtccctggacaaaggacaaatc 
R:   gctcattctcacagcccag 
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Patient fibroblast time-lapse imaging 
 
Cells were plated into High-Q4 culture dishes (Nikon) for live imaging, and treated with 
2.5mM thymidine for 16 hours for synchronization. Cells were then washed and released 
into 15% FBS in DMEM and placed on a Biostation IMQ live imaging microscope 
equipped with a 37oC incubator. Phase contrast images (distance between z sections: 
2µm) were captured at 2-minute intervals for 24 hours. Analysis was done using Nikon 
NIS-Elements Viewer software. 
 
 
Patient fibroblast colony forming assays 
 
For colony assays, 500 cells/10-cm dish were plated in 4 replicates. Cells were cultured 
for 11 days with varying doses of MMC and then plates were washed with 1x PBS and 
stained with methylene blue to highlight colonies. 
 
 
Patient fibroblast cell cycle assays 
 
To evaluate fibroblast cell cycle profiles after MMC treatment, patient fibroblasts were 
treated with 120nM of MMC for 2 hours, then washed and released into growth media for 
24 hours. Cells were then harvested using HyQTase Cell Detachment reagent (GE Life 
Sciences), washed with PBS, and fixed in 70% ethanol at -20oC overnight. Cells were 
then pelleted, washed with PBS, and stained with FxCycle PI/RNase Staining Solution 
(Life Technologies). At least 10,000 events were acquired on a BD FacsCanto Flow 
cytometer, and cell cycle profiles were obtained using FlowJo software. 
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To analyze SAC function of fibroblasts, transduced cells were plated onto coverslips and 
treated with 200nM taxol for 22 hours. Coverslips were fixed in 4% paraformaldehyde 
for 15 minutes, and then stained for alpha tubulin (1:100) and mounted in pro-long 
diamond antifade mountant with DAPI as described in Chapter one. Cells were visualized 
at 60x on a Deltavision deconvolution microscope, and the percentage of mitotic versus 
multinucleated cells was determined. At least 200 cells/experimental group were counted, 
and statistics was performed using Fisher’s exact test. 
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RESULTS 
 
 
CDK1 phosphorylates FANCC to localize FANCC to the mitotic spindle 
 
CDK1 was identified as a binding partner of FANCC nearly two decades ago (98) before 
the mitotic functions of FANCC were discovered. Given the importance of CDK1 kinase 
activity in regulating mitotic exit (101), we hypothesized that FANCC is a target for 
CDK1 phosphorylation. To test this hypothesis, we performed an in vitro kinase assay, in 
which recombinant cdk1 (cdc2-cyclin B1) was incubated with increasing amounts of 
recombinant FANCC in the presence of radioactive [P32] γ-ATP. Indeed, we detected 
phosphorylation of FANCC in vitro (Fig. 18) by CDK1. Interestingly, the ability of 
CDK1 to phosphorylate the general substrate histone H1 did not change with increasing 
doses of FANCC, indicating that the presence of FANCC does not alter CDK1 kinase 
activity in vitro. 
 
 
CDK1 phosphorylates numerous substrates during mitosis to regulate substrate 
localization and function. To explore whether CDK1 activity is required for FANCC 
localization at the mitotic spindle, we treated HeLa cells with a low dose of the CDK1- 
specific inhibitor RO-3306 and observed FANCC localization by immunofluorescence. 
Interestingly, FANCC localization to the mitotic spindle in metaphase cells was lost in 
the presence of RO-3306 (Fig. 19A). Western blotting of FANCC expression showed no 
difference in total protein levels between untreated and RO-3306-treated samples (Fig. 
19B). 
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Next, we used phosphorylation site prediction software to predict what residue(s) on 
FANCC may be phosphorylated by CDK1. We identified two hits, serine 540 and serine 
543, (Fig. 20) that were predicted through multiple independent queries (NetPhos 2.0, 
PhosphoNet, and NetPhosK software). These residues had prediction scores > 0.9, and 
are located in the C-terminus of FANCC, the region of FANCC known to bind CDK1. 
Using a FANCC-DDK tagged pCMV6 plasmid, we performed site directed mutagenesis 
to generate S543A and S540A DDK-tagged phospho-dead mutant constructs. We then 
stably transfected the DDK-tagged FANCC mutants, along with wildtype FANCC-DDK 
into HeLa cells. Using an anti-DDK antibody to visualize localization of the tagged 
FANCC proteins during mitosis, we observed spindle localization of FANCC-DDK and 
S540A-DDK proteins (Fig. 21). However, S543A-DDK failed to localize to the spindle 
(Fig. 21), identifying serine 543 on FANCC as the site for CDK1 phosphorylation. 
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Figure 18. CDK1 phosphorylates FANCC in vitro. In vitro kinase assay demonstrates 
dose-dependent phosphorylation of recombinant FANCC by cdc2-cyclin B1 in the 
presence of radioactive ATP. 
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Figure 19. Pharmacologic CDK1 inhibition disrupts FANCC localization to the 
mitotic spindle. (A) FANCC (red) localization to the mitotic spindle (right) is lost upon 
treatment with CDK1-inhibitor RO-3306 (left). Images represent slices (200nm) taken at 
100x on a Deltavision deconvolution microscope and deconvolved using Softworx 
software. Fancc protein expression in HeLa lysates was not affected by CDK1 inhibition 
(B, C). Quantification was performed using a Licor (Odyssey) CLx imaging system (n = 
6 recplicates/treatment group), and a student’s t-test was used to determine significance. 
Error bars represent SD. 
73  
 
 
 
72 
 
 
 
Figure 20. Predicted CDK1-phosphorylation sites on FANCC. Putative 
phosphorylation sites (asterisk) were predicted using NetPhos 2.0, PhosphoNet, and 
NetPhosK sites, and had a prediction score > 0.90. 
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Figure 21. Phosphorylation at S543 is required for mitotic localization of FANCC. 
 
(A) HeLa cells transfected with FANCC-DDK, S540A-DDK, or S543A-DDK were stained 
with anti-alpha tubulin (green) to mark the mitotic spindle and anti-DDK (red). Images 
represent one slice (distance between z sections: 0.2μm) of an image stack from the 
deconvolution microscope (100x magnification). (B) Western of DDK expression in 
HeLas post-transfection. 
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FANCC SAC function requires CDK1-dependent phosphorylation 
 
To explore whether phosphorylation at site 543 is important for FANCC mitotic function, 
we subcloned the genes encoding the FANCC-DDK and mutants into lenti-vectors and 
transduced a FANCC-deficient patient fibroblast primary cell line termed BKBK with the 
constructs. We sequenced DNA isolated from BKBK cells, and identified a bilallelic two 
base pair deletion (c.377_378del) in Exon 4 causing a frame shift (Fig. 22). After 
transduction and selection, we confirmed expression of our constructs by western blotting 
for both FANCC and DDK expression (Fig. 23). 
 
 
To test whether phosphorylation of site 543 on FANCC was essential for the ability of 
FANCC to regulate the SAC, we quantified the time from NEB to anaphase onset via 
time lapse imaging of BKBK-empty-DDK, BKBK-FANCC-DDK, and BKBK-S543A-DDK 
fibroblasts. BKBK-FANCC-DDK cells demonstrated a longer duration of NEB to 
anaphase onset than either BKBK-empty-DDK or BKBK-S543A-DDK cells (Fig. 24A). 
Faster time through mitosis is suggestive of impaired SAC function. SAC function in 
these cells was also directly challenged by exposure to 200nM taxol and subsequent 
immunofluorescence to identify mitotic arrested cells versus multinucleated cells that had 
broken through arrest. While addition of FANCC-DDK to the BKBK cells rescued the 
SAC breakthrough of BKB-empty cells, addition of S543A-DDK failed to rescue the 
multinucleation phenotype seen in taxol (Fig. 24B). Taken together, these experiments 
suggest that phosphorylation of site 543 is crucial to the SAC function of FANCC. 
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Given FANCC’s essential role in protecting genomic instability during both interphase 
and mitosis, we asked whether the S543A mutation would disrupt FANCC’s interphase 
DNA repair function. Upon exposure to the DNA crosslinker mitomycin C (MMC), 
S543A-DDK cells fail to rescue the G2-arrest seen in BKBK-empty-DDK patient 
fibroblasts (Fig. 25A). Additionally, BKBK cells transduced with S543A-DDK maintain 
hypersensitivity to MMC in colony forming assays (Fig. 25B), a hallmark feature of FA. 
Interestingly, phosphorylation of S543 is also necessary to preserve the DDR function of 
FANCC. 
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Figure 22. Sanger sequencing of FANCC patient fibroblast primary cell line BKBK. 
SnapGene software was used to align sequence with reference genomic FANCC 
sequence. The cell line was found to have bilallelic mutation c.377_378del in Exon 4, 
causing a frame shift and likely a truncated protein. 
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Figure 23. Confirmation of construct expression by western in FANCC-deficient 
BKBK patient fibroblasts after transduction and selection. 
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Figure 24. CDK1-dependent phosphorylation of S543A is required for FANCC SAC 
function. (A) Quantification of timing from nuclear envelope breakdown (NEB) to 
anaphase onset in mitotic BKBK cells transduced with empty-DDK, FANCC-DDK, or 
S543A-DDK. Time-lapsed phase contrast movies were acquired on a Nikon Biostation 
live imaging scope, and statistics represent comparisons to BKBK+empty-DDK via one- 
way ANOVA with Dunnet’s multiple comparisons test. (B) SAC challenge of BKBK 
cells transduced with empty-DDK, FANCC-DDK, S543A-DDK, or S540A-DDK. The 
percentage of pHH3+ cells was quantified, and significance determined using Fisher’s 
exact test. Significance is shown compared to BKBK+empty-DDK; *** p < 0.001 with p 
< 0.017 considered significant to account for multiple comparisons. 
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Figure 25. Phosphorylation of FANCC at S543 is necessary for FANCC interphase 
DDR function. (A) After exposure to MMC, S543A-DDK cells fail to rescue the G2- 
arrest seen in BKBK-empty-DDK patient fibroblasts. (B) BKBK cells transduced with 
S543A-DDK maintain hypersensitivity to MMC, a hallmark feature of FA. Statistical 
significance was determined by two-way ANOVA, and p values represent comparisons 
with BKBK-FANCC-DDK,  *** p < 0.001, **** p <0.0001. 
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FANCC interacts with the kinetochore protein ZWINT 
 
Although we identified CDK1 phosphorylation as important for FANCC SAC function, 
the signaling mechanism by which phospho-FANCC regulates the SAC is still unclear. 
Another research group previously performed a yeast-two hybrid screen to identify 
interactors of FANCC (117), and the kinetochore protein ZWINT was listed as an 
unvalidated hit from the screen. Given ZWINT’s importance in binding ZW10 to ensure 
stable ZW10 kinetochore localization (110), an important step in RZZ recruitment and 
SAC activation, we confirmed this interaction biochemically in HeLa cells. Indeed, co- 
immunoprecipitation experiments demonstrated that FANCC and ZWINT are together in 
a protein complex (Fig. 26). 
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Figure 26. FANCC interacts with the kinetochore protein ZWINT. 
Immunoprecipitation of FANCC (left) and blotting for ZWINT, and pulldown of ZWINT 
(right) and blotting for FANCC in HeLa lysates demonstrate FANCC-ZWINT binding. 
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Loss of FANCC impairs stable localization of ZW10 at prometaphase kinetochores 
Because FANCC regulates the SAC, and ZWINT is recruited to unattached KTs to 
activate downstream SAC effectors, we explored whether FANCC is required to recruit 
Zwint to the KT. Using our FANCC-deficient patient fibroblast line and an isogenic 
FANCC-corrected line as a control, we did immunofluorescence imaging of ZWINT in 
prometaphase cells. Although FANCC and ZWINT are binding partners, loss of FANCC 
did not impact ZWINT KT recruitment (Fig. 27). ZWINT is known to recruit ZW10, a 
member of the RZZ complex, to the KT to facilitate the SAC response. Interestingly, we 
observed disrupted ZW10 KT localization in FANCC-deficient fibroblasts (Fig. 28), 
suggesting that FANCC-ZWINT binding may be required for ZW10 recruitment and 
SAC activation at the KT. ZW10, as a member of the RZZ complex, is known to recruit 
the SAC effector MAD2 to the kinetochore, and so we asked whether loss of FANCC 
would disrupt MAD2 kinetochore localization. Indeed, we observed decreased MAD2 
recruitment to prometaphase KTs in FANCC-deficient patient fibroblasts (Fig. 29). 
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Figure 27. Loss of FANCC does not disrupt ZWINT kinetochore localization during 
prometaphase. Representative images FANCC corrected and uncorrected patient 
fibroblasts stained with anti-Zwint antibody (white) and DAPI to highlight DNA. 
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Figure 28. Loss of FANCC impairs stable localization of ZW10 at prometaphase 
kinetochores. (A) Representative images of ZW10 (white) localization to kinetochore 
(marked by Zwint stain, green) during prometaphase in FANCC-deficient and FANCC- 
corrected fibroblasts. Quantification in Imaris depicts less ZW10+ kinetochores (B) and 
decreased maximum ZW10 fluorescence intensity at the kinetochore (C) in FANCC- 
deficient patient fibroblasts. At least 500 kinetochores/group were analyzed, and statistics 
were obtained via student’s t-test. 
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Figure 29. Loss of FANCC impairs MAD2 localization to the prometaphase 
kinetochore. (A) Representative images of MAD2 (white) localization to the CENPA+ 
kinetochores (green) in FANCC-corrected and uncorrected patient fibroblasts. 
Quantification demonstrates decreased percentage of kinetochores with MAD2 positivity 
 
(B) and decreased fluorescence signal intensity of MAD2 at kinetochores (C) in FANCC- 
deficient cells. At least 300 kinetochores/cell line were analyzed using Imaris software, 
and statistical significance was established using Fisher’s exact test (B) and student’s t- 
test (C). 
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CDK1-dependent phosphorylation of FANCC is necessary to recruit ZW10 to the 
prometaphase kinetochore 
Having established the importance of CDK1 phosphorylation for FANCC function, we 
asked whether this phosphorylation event is necessary for FANCC’s ability to recruit 
ZW10 to the KT. Interestingly, pharmacologic inhibition of CDK1 in HeLa cells 
disrupted ZW10 localization to the kinetochore during prometaphase (Fig. 30A-C), while 
ZW10 total protein expression was unaffected (Fig. 30D-E). More specifically, ZW10 
expression at the KT was decreased in BKBK cells expressing the phospho-dead S543A- 
DDK compared to BKBK-FANCC-DDK cells (Fig. 31). Thus phosphorylation of FANCC 
at S543 by CDK1 regulates the SAC by facilitating ZW10 recruitment to the KT. 
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Figure 30. Pharmacologic inhibition of CDK1 during mitosis disrupts ZW10 
kinetochore recruitment. (A) Immunofluorescence images of ZW10 localization 
(white) in untreated and RO-3306 –treated HeLa cells in prometaphase. CENPA (green) 
was used as a kinetochore marker, and DNA is shown in blue. Quantification 
demonstrates less ZW10+ kinetochores (B) and decreased ZW10 kinetochore 
fluorescence intensity (C) upon CDK1 inhibition. At least 2000 kinetochores were 
quantified using Imaris Bitplane software. Total protein expression of ZW10 in HeLa 
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lysates was not affected by CDK1 inhibition (D, E). Quantification (E) was performed 
using Licor Odyssey software and represents at least 6 replicates. Error bars represent 
SEM, with student’s t-test used for statistics. 
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Figure 31. Phosphorylation of FANCC at S543 is necessary for stable ZW10 
kinetochore recruitment. (A) Representative images of FANCC-deficient BKBK 
prometaphase fibroblasts expressing either FANCC-DDK or S543A-DDK. DNA is shown 
in blue, and cells were stained with anti-ZWINT (green) and anti-ZW10 (white) 
antibodies. Quantification shows less ZW10+ kinetochores (B) and decreased maximum 
ZW10 fluorescence intensity at kinetochores (C) in BKBK-S543A-DDK cells. Image 
analysis was performed using Imaris Bitplane software, with at least 500 kinetochores 
analyzed per group. Statistical significance was determined using student’s t-test. 
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DISCUSSION 
 
 
We have elucidated a novel CDK1-FANCC-ZW10 signaling axis (Fig. 32) that provides 
a mechanism by which FANCC regulates the SAC to prevent aneuploidy and genomic 
instability. We now know that CDK1 phosphorylates FANCC at serine 543, and that this 
phosphorylation event is necessary for the mitotic localization of FANCC and its SAC 
function. We have also demonstrated that phosphorylation at S543 is needed for the KT 
recruitment of ZW10, which promotes the recruitment of Mad1/Mad2 to activate the 
SAC. 
 
 
FANCC-RZZ signaling 
 
We have shown that phosphorylation of FANCC is required for ZW10 kinetochore 
recruitment. ZW10 is a member of the RZZ complex, consisting of ROD, ZWILCH and 
ZW10.  ZW10 is required for the recruitment of ROD to the KT, and vice versa (118). 
We hypothesize that loss of FANCC disrupts KT localization of the RZZ complex as a 
whole, in addition to ZW10, and are currently examining KT recruitment of ROD and 
ZWILCH in FANCC-deficient cells. 
 
 
While we demonstrate that FANCC is necessary for ZW10 KT recruitment, the process 
by which this occurs is still unclear. We have shown that FANCC binds Zwint during 
prometaphase, but have been unable to co-immunoprecipitate ZW10 and FANCC (data 
not shown), suggesting that FANCC indirectly recruits ZW10. Loss of FANCC results in 
impaired recruitment of ZW-10, but not Zwint, to KTs. Zwint must be phosphorylated by 
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Aurora kinase B in order to interact with ZW-10 and facilitate ZW-10 recruitment to the 
KT. Pharmacologic inhibition of Aurora kinase B activity results in impaired recruitment 
of ZW-10, but not Zwint, to the KT (111). Based on the phenotypic similarities between 
loss of FANCC and inhibition of Aurora kinase B (Table 3), we hypothesize that 
FANCC may facilitate Aurora kinase B-mediated phosphorylation of Zwint to ensure KT 
recruitment of the RZZ complex and SAC activation. 
 
 
The RZZ complex, in addition to facilitating SAC response, also functions to mediate 
silencing of the SAC once the checkpoint has been satisfied. The RZZ complex recruits 
dynein to the KT, allowing dynein-mediated streaming of SAC proteins from the KT at 
the onset of anaphase (119). Given FANCC’s role in mediating KT recruitment of ZW10, 
FANCC may play a role not only in SAC activation but also SAC silencing. More work 
will be needed to explore this possibility. 
 
 
CDK1 and the FA family 
 
While we have shown that CDK1 phosphorylates FANCC, others have previously 
demonstrated that FANCG is also phosphorylated by CDK1 during mitosis (120). 
However, it is not yet known whether CDK1 phosphorylation of FANCG is required for 
mitotic SAC function of FANCG. It is possible that CDK1 phosphorylation may play an 
integral role in regulating SAC function of multiple members of the FA pathway. Further 
studies are needed to explore this possibility. 
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Significance of serine 543 on FANCC 
 
Our studies have demonstrated that phosphorylation of serine 543 on FANCC is essential 
not only to its mitotic SAC function, but also to its interphase DNA damage repair 
function. The mutant S543A demonstrated hypersensitivity to low-dose MMC and a 
characteristic G2 arrest upon exposure to higher does of MMC. While this demonstrates 
that addition of the S543A fails to rescue the DNA repair defect of FANCC-deficient 
fibroblasts, it is unknown whether CDK1 is the kinase responsible for the interphase 
phosphorylation at this site. The importance of phosphorylation of serine 543 for both 
interphase and mitotic function of FANCC is intriguing, and suggests that these 
seemingly separate functions of FANCC may be linked. Likewise, mutation of the 
CDK1-phosphorylation site in FANCG resulted in MMC hypersensitivity and G2 arrest 
after MMC treatment (120). In addition to FA proteins, many other SAC proteins have 
been shown to protect genomic instability not only during mitosis but also via DDR. The 
SAC protein Bub1 becomes phosphorylated by ATM to participate in DDR (121). 
Phosphorylation of CHK2, an effector of DDR signaling, by the KT protein hMps1 is 
necessary for G2/M arrest after DNA damage (122). These proteins play distinct but 
complementary roles in both SAC and DDR checkpoints to protect genomic integrity. 
Likewise, we now know not only that FANCC regulates the SAC and DDR, but that its 
function in both checkpoints is at least in part, dependent on the same phosphorylation 
site. 
 
 
Identification of this CDK1 phosphorylation site provides insight into our understanding 
of how disease may be correlated to patient FANCC mutation status. There are two 
published records of patients with a mutation at site 543. One of these is an amino acid 
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substitution S543K “variant of uncertain significance” recorded in ClinVar. The Cancer 
Genome Atlas (TCGA) has a record of one patient with non-small cell lung cancer 
(NSCLC) that has a nonsense mutation starting at serine 543 (123). Additionally, many 
of the mutations in FANCC found in cancers recorded in the TCGA and COSMIC 
(catalogue of somatic mutations in cancer) databases are located in the C-terminus 
CDK1-binding region or cause a premature stop codon such that the C-terminus of 
FANCC is not translated (Fig. 33). Given our knowledge that disruption of CDK1- 
dependent FANCC phosphorylation disrupts both DNA repair and SAC functions of 
FANCC, we would predict that many of these mutations would have loss of function for 
the same reason. 
 
 
Overall, we demonstrate via in vivo modeling (CHAPTER ONE) that Fancc and 
Mad2 cooperate to regulate the SAC, and we define a CDK1-FANCC-ZW10 
signaling axis (CHAPTER TWO) as a mechanism whereby FANCC facilitates 
SAC function. 
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Figure 32. Proposed model for a CDK1-FANCC-ZW10 SAC signaling axis. 
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Phenotype 
Inhibition of Aurora 
Kinase B 
Loss of FANCC 
ZWINT KT localization unaffected unaffected 
ZW10 KT localization impaired impaired 
SAC disrupted? yes yes 
 
Table 3. Phenotypic comparison of the effects of inhibition of Aurora Kinase B and 
loss of FANCC. 
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Figure 33. Depiction of amino acid mutations in the CDK1-binding region of 
FANCC in various cancers. Mutation information was obtained from TCGA and 
COSMIC databases. Asterisk represents truncating nonsense mutation. 
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FUTURE DIRECTIONS 
 
It is known that the FA family of proteins functions in a complex during interphase to 
mediate DDR. As we learn more about the role of various FA proteins during mitosis, 
one main question emerges. Do the FA proteins work in concert or in a complex during 
mitosis to protect genomic integrity? During mitosis, the FA proteins localize to various 
mitotic structures. The majority of the FA proteins localize to the centrosome, and 
FANCA and FANCC are also expressed on the spindle. We also now know that CDK1 
phosphorylates FANCC and FANCG. It is possible then that FA proteins act in concert in 
mitosis to regulate certain mitotic functions, while some FA proteins, such as FANCC, 
have independent roles during mitosis. We will explore the possibility of a mitotic FA 
complex by co-immunoprecipitation studies in the future. We will also determine 
whether loss of certain FA proteins impacts the mitotic localization of other FA proteins 
using our FA-deficient fibroblasts. 
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